8-K: Coya Therapeutics Announces Positive Clinical Trial Data and Third Quarter 2024 Financial Results

Coya Therapeutics reported positive results from an Alzheimer's disease study, provided a corporate update, and announced its third quarter 2024 financial results.

Summary

• Coya Therapeutics, a clinical-stage biotechnology company, announced its financial results for the quarter ended September 30, 2024, and provided a corporate update.
• The company reported positive results from a double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD).
• Coya has filed patents for COYA 301 in combination with Glucagon-Like Peptide-1 (GLP-1) receptor agonists.
• Arun Swaminathan, Ph.D., was promoted to Chief Executive Officer, effective November 1, 2024, with Howard Berman transitioning to Executive Chairman.
• Preclinical data showed anti-inflammatory effects of COYA 302 in a mouse model of Parkinson's disease (PD).
• The company has aligned with the FDA on non-clinical data requirements for a Phase 2b trial of COYA-302 in Amyotrophic Lateral Sclerosis (ALS).
• A Phase 1 investigator-initiated trial (IIT) combining LD IL-2 + CTLA4-Ig has begun in patients with Frontotemporal Disease (FTD).
• Coya expects to release additional clinical data from the Phase 2 LD IL-2 trial in AD in Q1 2025.
• The company anticipates submitting COYA 301/GLP-1 combination data for publication in Q1/Q2 2025.
• Coya plans to submit additional data to support the start of the COYA-302 Phase 2 trial in ALS in Q2 2025.
• Upon IND acceptance and first patient dosing of COYA-302 in ALS, Coya is eligible to receive $8.4 million in milestone payments from Dr. Reddy's Laboratories (DRL).
• The company expects to release top-line clinical data for the LD IL-2 + CTLA4-Ig trial in FTD in the second half of 2025.
• Coya's cash and cash equivalents were $31.1 million as of September 30, 2024.
• Research and development expenses were $2.2 million for the three months ended September 30, 2024, compared to $1.6 million for the same period in 2023.
• General and administrative expenses were $2.2 million for the three months ended September 30, 2024, compared to $2.0 million for the same period in 2023.
• The net loss was $4.0 million for the three months ended September 30, 2024, compared to a net loss of $3.4 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with encouraging clinical data and upcoming milestones, but also acknowledges the financial challenges of a clinical-stage biotech company. The sentiment is positive but tempered by the inherent risks of drug development.

Positives

• Positive results were reported from an investigator-initiated study of LD IL-2 in Alzheimer's disease.
• The company has made progress in advancing its pipeline of neurodegenerative treatments.
• Coya has aligned with the FDA on the non-clinical data needed for the Phase 2b trial of COYA-302 in ALS.
• The company is eligible for a significant milestone payment upon the start of the COYA-302 trial in ALS.
• Coya has a strong cash position of $31.1 million as of September 30, 2024.
• The company has a clear path forward for the completion of the potential pivotal trial of COYA-302 in ALS.
• The company has a multi-targeted approach to treating neurodegenerative diseases, which differentiates it from other companies.

Negatives

• The company reported a net loss of $4.0 million for the three months ended September 30, 2024, which is higher than the $3.4 million loss for the same period in 2023.
• Research and development expenses increased to $2.2 million for the quarter, up from $1.6 million in the same period last year.
• General and administrative expenses also increased to $2.2 million for the quarter, up from $2.0 million in the same period last year.

Risks

• The company's future success depends on the outcome of its clinical trials.
• There are risks associated with the development and commercialization of new therapeutics.
• The company may need to raise additional capital in the future to fund its operations.
• The company operates in a competitive and rapidly changing environment.
• There are risks associated with the company's dependence on third-party manufacturers.

Future Outlook

Coya anticipates a busy and productive 2025 with multiple milestones, clinical data releases, and catalysts, including the start of Phase 2 trials for COYA 302 in ALS and FTD.

Management Comments

• Coya CMO, Dr. Fred Grossman, stated that they are pleased with the constructive discussion with the FDA and have clarity on the non-clinical data needed to support the start of the Phase 2 study of COYA-302 in patients with ALS.
• Coya CEO Arun Swaminathan, Ph.D., said he is very encouraged by the progress in 2024 and believes it opens a wide array of strategic opportunities in 2025.
• Swaminathan also stated that the recent capital raise provides additional flexibility and cushion for the company to execute on its goals.

Industry Context

Coya's focus on neuroinflammation and combination therapies aligns with the growing interest in addressing the underlying causes of neurodegenerative diseases. The company's approach to enhancing Treg function is a novel strategy in the field.

Comparison to Industry Standards

• Coya's approach of combining LD IL-2 with CTLA4-Ig is unique compared to companies focusing on single-target therapies for neurodegenerative diseases.
• The company's focus on Treg modulation is a relatively new area of research, with few direct comparables in terms of clinical-stage companies.
• While companies like Biogen and Roche have significant presence in neurodegenerative disease, Coya's approach is differentiated by its focus on immune modulation.
• The $8.4 million milestone payment from Dr. Reddy's Laboratories is a positive sign of external validation of Coya's technology.
• The company's cash position of $31.1 million is relatively modest compared to larger pharmaceutical companies, but is sufficient to fund its near-term clinical trials.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical data and upcoming milestones.
• Employees may be motivated by the company's progress and strategic opportunities.
• Patients with neurodegenerative diseases may benefit from the development of new treatments.
• Strategic partners may be interested in collaborating with Coya on its innovative therapies.

Next Steps

• Release additional clinical data from the Phase 2 LD IL-2 trial in AD in Q1 2025.
• Submit COYA 301/GLP-1 combination data for publication in Q1/Q2 2025.
• Submit additional data to support the start of the COYA-302 Phase 2 trial in ALS in Q2 2025.
• Release top-line clinical data for the LD IL-2 + CTLA4-Ig trial in FTD in the second half of 2025.
• File IND for the COYA-302 Phase 2 trial in FTD in the second half of 2025.

Key Dates

Keywords

Coya Therapeutics, Neurodegenerative Diseases, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Frontotemporal Dementia, Regulatory T cells, COYA 302, Low-dose Interleukin-2, Clinical Trials, Biologics, Neuroinflammation